The Metabolic Syndrome: A Common Hyperinsulinemic Disorder With Severe Health Effects

Metabolic syndrome is a recently defined medical disorder and now considered to be an epidemic. It includes several diseases stemming typically from overweight or obesity. Clinical characteristics include abnormal blood lipids, insulin resistance, abdominal obesity, high blood pressure (hypertension), and low serum high-density lipoprotein cholesterol. Individuals with this syndrome are typically not treated for any of their abnormalities until they are seriously affected by one of the diseases. Metabolic syndrome is more common in men and is becoming recognized even among children and adolescents. Metabolic syndrome arises because of altered metabolic pathways, including insulin resistance, and excessive consumption of food energy not balanced by energy expenditure in physical activities. The underlying pathophysiology is an abnormality in the metabolism of triglycerides involving fat cells, muscle cells, and other extrahepatic cells. The major diseases that result from these abnormalities are obesity, hypertension, diabetes mellitus type 2, and cardiovascular diseases (coronary heart disease and stroke). Prevention is best, but when the syndrome exists, treatment focuses on weight loss to achieve a healthy body weight

[1]  C. Lardinois,et al.  Syndrome X: medical nutrition therapy. , 2009, Nutrition reviews.

[2]  B. Duncan,et al.  Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study). , 2004, The American journal of cardiology.

[3]  D. Cherry,et al.  National Ambulatory Medical Care Survey: 2002 summary. , 2004, Advance data.

[4]  K. Frayn The glucose-fatty acid cycle: a physiological perspective. , 2003, Biochemical Society transactions.

[5]  W. Dietz,et al.  Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. , 2003, Archives of pediatrics & adolescent medicine.

[6]  N. Goldenberg,et al.  Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. , 2003, Metabolism: clinical and experimental.

[7]  R. Green NASH—hepatic metabolism and not simply the metabolic syndrome , 2003, Hepatology.

[8]  S. Teutsch,et al.  NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. , 2003, Diabetes.

[9]  A. Balen,et al.  Polycystic ovary syndrome--a systemic disorder? , 2003, Best practice & research. Clinical obstetrics & gynaecology.

[10]  A. Scheen,et al.  NONALCOHOLIC STEATOHEPATITIS AND INSULIN RESISTANCE : INTERFACE BETWEEN GASTROENTEROLOGISTS AND ENDOCRINOLOGISTS , 2003, Acta clinica Belgica.

[11]  E. Bodart,et al.  BRONCHIOLITIS MANAGEMENT BY THE BELGIAN PAEDIATRICIAN : DISCREPANCIES BETWEEN EVIDENCE-BASED MEDICINE AND PRACTICE , 2003, Acta clinica Belgica.

[12]  H. Wyatt,et al.  Outpatient management of obesity: a primary care perspective. , 2002, Obesity research.

[13]  F Xavier Pi-Sunyer,et al.  The obesity epidemic: pathophysiology and consequences of obesity. , 2002, Obesity research.

[14]  K. Flegal,et al.  Prevalence and trends in obesity among US adults, 1999-2000. , 2002, JAMA.

[15]  Rebecca A F Murray Recognizing the Signs of Metabolic Syndrome and Polycystic Ovary Syndrome in a Caucasian Adolescent Girl: Differentiating Type 2 From Type 1 Diabetes , 2002 .

[16]  J. Reusch Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome. , 2002, The American journal of cardiology.

[17]  Nghi Ly,et al.  National Hospital Ambulatory Medical Care Survey: 2000 outpatient department summary. , 2002, Advance data.

[18]  D. Ludwig The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. , 2002, JAMA.

[19]  A. O’Sullivan,et al.  Body composition and energy metabolism in chronic renal insufficiency. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  W. Dietz,et al.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. , 2002, JAMA.

[21]  G. Reaven Multiple CHD risk factors in type 2 diabetes: beyond hyperglycaemia , 2002, Diabetes, obesity & metabolism.

[22]  F Vinicor,et al.  The continuing epidemics of obesity and diabetes in the United States. , 2001, JAMA.

[23]  D. Singer,et al.  Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham offspring study. , 2001, Diabetes care.

[24]  B. Egan,et al.  Insulin resistance and cardiovascular disease. , 2001, American journal of hypertension.

[25]  A. Ramirez,et al.  The metabolic syndrome and related cardiovascular risk , 2001, Current hypertension reports.

[26]  P. Perin,et al.  SYMPATHETIC NERVOUS SYSTEM, DIABETES, AND HYPERTENSION , 2001, Clinical and experimental hypertension.

[27]  J W Erdman,et al.  AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. , 2000, Circulation.

[28]  E. Riboli,et al.  Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. , 2000, Journal of the National Cancer Institute.

[29]  Sheila M. Williams,et al.  More Broken Bones: A 4‐Year Double Cohort Study of Young Girls With and Without Distal Forearm Fractures , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[30]  K. Frayn Visceral fat and insulin resistance — causative or correlative? , 2000, British Journal of Nutrition.

[31]  J. Neutel,et al.  Differing Roles of Body Mass and the Renin-Angiotensin System in Mediating the Hypertension Syndrome , 2000, American Journal of Nephrology.

[32]  L. Mandarino,et al.  Fuel selection in human skeletal muscle in insulin resistance: a reexamination. , 2000, Diabetes.

[33]  Nicola Abate Obesity and cardiovascular disease. Pathogenetic role of the metabolic syndrome and therapeutic implications. , 2000, Journal of diabetes and its complications.

[34]  P. Björntorp,et al.  Hypertension and the Metabolic Syndrome: Closely Related Central Origin? , 2000, Blood pressure.

[35]  P. Fontanarosa Patients, physicians, and weight control. , 1999, JAMA.

[36]  D. Galuska,et al.  Are health care professionals advising obese patients to lose weight? , 1999, JAMA.

[37]  A. Folsom,et al.  Elevated fasting insulin predicts incident hypertension: the ARIC study. Atherosclerosis Risk in Communities Study Investigators. , 1999, Journal of hypertension.

[38]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[39]  Uk-Prospective-Diabetes-Study-Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[40]  S. Julius,et al.  Effect of sympathetic overactivity on cardiovascular prognosis in hypertension. , 1998, European heart journal.

[41]  K. Flegal,et al.  Prevalence of Diabetes, Impaired Fasting Glucose, and Impaired Glucose Tolerance in U.S. Adults: The Third National Health and Nutrition Examination Survey, 1988–1994 , 1998, Diabetes Care.

[42]  S. Schappert National Hospital Ambulatory Medical Care Survey: 1992 Emergency Department Summary. , 1997, Vital and health statistics. Series 13, Data from the National Health Survey.

[43]  A. Mimran,et al.  Combined renal effects of overweight and hypertension. , 1995, Hypertension.

[44]  E. Giovannucci Insulin and colon cancer , 1995, Cancer Causes & Control.

[45]  K. Flegal,et al.  Increasing Prevalence of Overweight Among US Adults: The National Health and Nutrition Examination Surveys, 1960 to 1991 , 1994 .

[46]  G. Reaven Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[47]  G. Reaven,et al.  Additive Hypoglycemic Effects of Drugs That Modify Free-Fatty Acid Metabolism by Different Mechanisms in Rats With Streptozocin-Induced Diabetes , 1988, Diabetes.

[48]  R. Califf,et al.  Metabolic syndrome: definition, pathophysiology, and mechanisms. , 2005, American heart journal.

[49]  R. Califf,et al.  Metabolic syndrome: evaluation of pathological and therapeutic outcomes. , 2005, American heart journal.

[50]  C. Champagne,et al.  Obesity and the Metabolic Syndrome: implications for dietetics practitioners. , 2004, Journal of the American Dietetic Association.

[51]  Brian P. Mulhall,et al.  Nonalcoholic steatohepatitis , 2004, Current treatment options in gastroenterology.

[52]  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. , 2002, Circulation.

[53]  R. Krauss,et al.  AHA scientific statement: AHA dietary guidelines: Revision 2000: A statement for healthcare professionals from the nutrition committee of the American Heart Association , 2001 .

[54]  M Nestle,et al.  Halting the obesity epidemic: a public health policy approach. , 2000, Public health reports.

[55]  Igor Sartori Increasing Prevalence of Overweight Among US Adults , 1996 .

[56]  E. Ferrannini Syndrome X. , 1993, Hormone research.

[57]  G. Shulman,et al.  On Diabetes: Insulin Resistance Cellular Mechanisms of Insulin Resistance , 2022 .